AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Immunological and Virological Prognostic Markers of Human Cytomegalovirus (HCMV) Congenital Infection in Pregnant Women With Primary HCMV Infection.

Recruitingn/aAges 18 Years - anyFemaleFondazione IRCCS Policlinico San Matteo di Pavia
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Human cytomegalovirus (HCMV) establishes a lifelong relationship with its host: primary infection is followed by a latency phase with intermittent reactivation episodes, despite a robust, long-lasting immune response. Primary and non-primary infection (the latter indicating both reactivation and re-infection) is usually asymptomatic in immunocompetent individuals. Apart from immunocompromised subjects, HCMV is potentially dangerous during pregnancy: the fetus may become infected and develop symptoms at birth or severe long-term sequelae in about 20% of cases (Stagno et al, JAMA 1986; Dollard et al, Rev Med Virol 2007). HCMV is the most common congenital infection with vertical transmission occurring in about 0.64% pregnancies (Cannon \& Davis, BMC Public Health 2005). Our studies on the T and B cell response to HCMV suggest that a delayed development of the immune response to HCMV prim

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Pregnant women \>18 years. * HCMV primary infection occurring within 26 weeks of gestation. * HCMV primary infection onset within 3 months before enrollment. * HCMV pre-conception (non-primary) infection and congenitally infected newborn Exclusion Criteria: * HBV, HCV, HIV infection. * Known immunodeficiency, immunosuppression or autoimmune disease. * Inability to comply with the requirements of the protocol.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy